Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06465823
Other study ID # 1042_OPBG_2016
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 11, 2023
Est. completion date September 30, 2026

Study information

Verified date June 2024
Source Bambino Gesù Hospital and Research Institute
Contact Paolo Alfieri
Phone 0668592735
Email paolo.alfieri@opbg.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the clinical efficacy of a known diuretic drug, Bumetanide, in terms of improvement of memory and psychological functioning in children and adolescents with Down syndrome (DS), in order to develop therapeutic strategies for cognitive and psychopathology aspects associated with the syndrome. The study also aims to identify possible predictors and biological and genetic markers related to the efficacy of the treatment. Recently, preliminary studies conducted on the animal model of Down syndrome have proven the efficacy of the drug Bumetanide in counteracting some brain anomalies related to communication between nerve cells (synaptic transmission) typical of the syndrome, with the effect of improving memory skills. Behaviour-enhancing effects have also been found in preliminary studies in humans with other neurodevelopmental disorders (e.g., autism spectrum disorders). The drug Bumetanide could therefore be useful in counteracting the biological mechanisms that cause some cognitive deficits associated with Down syndrome. The potential of this therapeutic approach will be tested through a clinical trial in a population of children and adolescent patients with DS, in a randomized placebo-controlled trial with a three-month treatment with Bumetanide. Participants will be randomly assigned to the experimental group that will receive the treatment (Bumetanide) vs the control/comparison group that will receive the placebo. Bumetanide is a diuretic drug that has been widely used in humans in the past with few side effects, is orally active, and is very inexpensive. 64 participants will be recruited.


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bumetanide
Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment. The patients will start the treatment with half of the full target dose during the first week: If the target dose is 0.5mg BID, only the morning dose will be administrated. If the target dose is 1.0 mg BID the dose will be 0.5 mg BID. If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg. If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing.
Placebo
Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.

Locations

Country Name City State
Italy Bambino Gesù Children's Hospital Rome

Sponsors (2)

Lead Sponsor Collaborator
Stefano Vicari Italian Institute of Technology (IIT)

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Cancedda L, Fiumelli H, Chen K, Poo MM. Excitatory GABA action is essential for morphological maturation of cortical neurons in vivo. J Neurosci. 2007 May 9;27(19):5224-35. doi: 10.1523/JNEUROSCI.5169-06.2007. — View Citation

Deidda G, Bozarth IF, Cancedda L. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci. 2014 May 22;8:119. doi: 10.3389/fncel.2014.00119. eCollection 2014. — View Citation

Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, Hadjikhani N, Ben-Ari Y. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012 Dec 11;2(12):e202. doi: 10.1038/tp.2012.124. — View Citation

Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M, Brosset P, Viellard M, Bernoux D, Rondeau S, Thummler S, Ravel D, Ben-Ari Y. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry. 2017 May 9;7(5):e1124. doi: 10.1038/tp.2017.101. No abstract available. — View Citation

Savardi A, Borgogno M, De Vivo M, Cancedda L. Pharmacological tools to target NKCC1 in brain disorders. Trends Pharmacol Sci. 2021 Dec;42(12):1009-1034. doi: 10.1016/j.tips.2021.09.005. Epub 2021 Oct 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Biosample PBMC (blood) for biomarkers Exploratory end-point - PBMCs will be analyzed from blood samples of all patients to identify possible biomarkers for response to treatment by evaluating the expression of NKCC1 and other genes (at RNA or protein levels) Day 1 and Day 90 ±3
Other Transcriptomic analysis by RNA-Seq assessment (on PBMCs samples) Exploratory end-point - All cohort patients will be analyzed for transcriptomic analysis by RNA-Seq. Total mRNA will be purified from PBMC and used for the mRNA-Seq library preparation Day 1, Day 90 ±3 and Day 150 ±4
Other Genomic assessment (on blood samples) Exploratory end-point - All participants will be analyzed by whole genome sequencing (both patients who respond to therapy and those who do not show any positive response). Genomic analysis will be performed on the pellet derived from centrifugation of the blood samples collected at visit 1, to obtain the corresponding plasma samples to be used for the proteomic analysis. Day 1
Other Proteomic (on plasma and PBMCs samples) assessment Exploratory end-point. Plasma and PBMC samples will be collected from all patients (both patients who respond to therapy and those who do not show any positive response). Five mL of peripheral venous blood samples x (supernatant) will be collected. Day 1, Day 90 ± 3 and Day 150 ± 4
Other Metabolomic (on urine samples) assessment Exploratory end-point: Urine samples will be collected from all patients (both patients who respond to therapy and those who do not show any positive response) to identify possible biomarkers for treatment response Day 1, Day 90 ± 3 and Day 150 ± 4
Primary Visual-Object long-term memory measures Visual-Object Learning test (PROMEA, Vicari, 2007) - Efficacy criterion. Test assesses long-term visual memory skills.The total raw score of the visual episodic memory trial, the raw learning scores for each immediate recall trial (R_Score T1, T2, T3) and the raw score of the deferred recall trial (R_ Score Deferred) will be evaluated. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Verbal long-term memory measure Verbal Learning test (PROMEA, Vicari, 2007) - Efficacy criterion. Test assesses long-term verbal memory skills. The raw learning scores for each immediate recall trial (R_ScoreT1, T2, T3) and the raw score of the deferred recall trial (R_ Score Deferred) will be taken into account. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Visual-Spatial long-term memory measure Visual-Spatial learning test (PROMEA, Vicari, 2007) - Efficacy criterion. Test assesses long-term spatial memory skills.The raw learning scores for each immediate recall trial (R_ScoreT1, T2, T3) and the raw score of the deferred recall trial (R_ Score Deferred) will be taken into account. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Long-term memory measures : recollection and familiarity Processing Dissociation Procedure - PDP (Costanzo et al., 2013 - Efficacy criterion. Test assesses recollection and familiarity processes to memory performance..In the Processing Dissociation Procedures (PDP) test, of hits alarms responses (H) and false alarms responses (F) will be considered for both the "Inclusion" and "Exclusion" conditions. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Long-term memory measure: associative memory Associative Memory (Costanzo et al., 2013) - Efficacy criterion. Test assesses recollection and familiarity processes to memory performance.The total raw scores for the "single item" and "associative item" condition and the learning raw scores for each trial of each condition (T1, T2, T3) will be evaluated. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Long-term measure - child's everyday memory The Observer Memory Questionnaire-Parent Form (OMQ-PF, Gonzalez et al., 2008) - Likert scale questionnaire, test assesses parental beliefs about their child's everyday memory.For the assessment of everyday memory skills, the raw total score will be considered. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Adaptive level ABAS II (Adaptive Behavior Assessment System Second Edition, Italian adaptation of Ferri R., Orsini A. e Rea M., Eds., 2014) - Efficacy criterion. Scale to obtain the parent's observations about the youth's behaviour and gives a complete overview of child and adolescent adaptive behaviours. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Executive measure Behavior Rating Inventory Executive Function Second Edition (BRIEF 2, Gioia et al., 2000) Inventory evaluates everyday behaviors associated with EF in home and educational environments.The standardized scores (T) of Inhibit, Self-Monitor, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Task-Monitor,and Organization of Materials scales will be evaluated. Behavioral Regulation Index (BRI), Emotional Regulation Index (ERI), Cognitive Regulation Index (CRI) and Global Executive Composite Score (GEC) also will be assessed. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Psychopathological measure - semi-structured diagnostic interview K-Sads-Present and Lifetime Version (K-SADS-PL) (Kaufman et al., 2004) - Efficacy criterion. Interview assesses psychopathology according to the DSM-5 criteria.The total raw score related to current symptoms reported by the participant's parents in the interview and the symptom/disease decoding scores related to each diagnostic category will be evaluated. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Psychopathological measure - behavioral and psychopathological aspects Conners' Parent Rating Scale -. Revised, Long Form (CPRS-R:L - Conners, 1997; Nobile, Alberti, & Zuddas, 2007) - Efficacy criterion. Questionnaire used parent's observations about the youth's behaviour and gives a complete overview of child and adolescent psychopathological disorders.The T scores of each scale of the questionnaire will also be evaluated. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Psychopathological measure - quantitative scale on anxiety symptoms Multidimensional Anxiety Scale For Children - (MASC-parent report form March, 1997) - Efficacy criterion. Questionnaire assesses anxiety symptoms.The standardized total score (T) and T scores of the separation anxiety (SP), GAD, social anxiety (SAT), obsessions and compulsions (OC), physical symptoms (PS:T) and harm avoidance (HA) scales will be evaluated. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Psychopathological measure - behavioural and emotional problems Child Behavior Checklist for Ages 6-18 - CBCL/6-18 (Achenbach e Rescorla, 2001) - Efficacy criterion. Questionnaire assesses behavioural and emotional problems in children and young people aged 6-18 years.The T-scores of each scale of the CBCL 6-18 questionnaire will be evaluated. Change from baseline (day 1) to 3 month (day 90 ± 3), day 150 ± 4
Secondary Quality of life PedsQL (PedsQL, JWVarni, 2004): measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. the raw scores of each scale (Physical , Emotional , Social , School) and the respective mean scores (Physical SC, Emotional Functioning ,Social Functioning , School Functioning), the physical index (T_Physical) , the psychosocial index (T_Psychosocial) and the mean total score (Total Score) of the questionnaire, will be evaluated. day 1/ day 7± 1/ day 31± 3/day 90 ± 3/day, day 150 ± 4
Secondary Quality of sleep Sleep Disorders SDSC (The Sleep Disturbance Scale for Children, Bruni et al., 1996) - Sleepiness inventory is used to obtain the parent's observations about sleep disorders in children in five subdomains.T scores of each scale will be evaluated. day 1/ day 7± 1/ day 31± 3/day 90 ± 3/day, day 150 ± 4
Secondary Bristol stool scale Quality of life Stooling (based on Bristol stool scale) - Diagnostic medical tool designed to classify the form of human faeces into seven categories (Type 1-7) Day 1, Day 7± 1, Day 31± 3, Day 90 ± 3, Day 150 ± 4
See also
  Status Clinical Trial Phase
Recruiting NCT04854122 - Blood Flow Regulation in Individuals With Down Syndrome - Training Study N/A
Completed NCT04020302 - Self-Monitoring Shopping Intervention N/A
Recruiting NCT01950624 - DS-Connect {TM}: The Down Syndrome Registry
Completed NCT04751136 - the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome Phase 2
Completed NCT04767412 - Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome Randomized Control Trial N/A
Completed NCT04536506 - Bobath and Vojta Therapy for DS N/A
Not yet recruiting NCT04037579 - Protocol for a Non-randomized Survey in Down Syndrome People Who Practice Sports. Self and Observers´ Perception.
Completed NCT02882698 - Performance Analysis in Down Syndrome on Mobile Phone N/A
Completed NCT01791725 - A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia Phase 2
Unknown status NCT01975545 - Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21 Phase 2
Completed NCT01808508 - Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome N/A
Terminated NCT00754052 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17 Phase 3
Terminated NCT00754013 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10 Phase 3
Completed NCT01256112 - Parent Supported Weight Reduction in Down Syndrome N/A
Completed NCT01313325 - Hippotherapy to Improve the Balance of Children With Movement Disorders N/A
Completed NCT01594346 - Multicenter Vitamin E Trial in Aging Persons With Down Syndrome Phase 3
Completed NCT05343468 - Life Skills Improved in Children With Down Syndrome After Using Assistive Technology N/A
Suspended NCT05755464 - Evaluation of Patients With Down Syndrome Compliance to Dental Therapy
Recruiting NCT04022460 - Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
Completed NCT04818437 - Effect of Core Stability Exercises and Balance Training in Postural Control Among Down Syndrome N/A